WebApr 6, 2024 · Editas Medicine (NASDAQ: EDIT) and Bluebird Bio (NASDAQ: BLUE) are both beaten-down gene-editing stocks. Editas' shares are down by 65% in the last 12 months, whereas Bluebird's have fallen by 40%. Web1 hour ago · Assuming a price of $2 million, that's a $64 billion opportunity. This price tag is by no means outrageous. Last year, Bluebird Bio earned approval for a gene-editing medicine called Zynteglo. The ...
FDA Approves Bluebird Bio’s Lentiviral Gene Therapy to Treat Beta ...
Web1 day ago · Last year, Australian drugmaker CSL Ltd set the list price of its gene therapy for blood disorder hemophilia B at a record $3.5 million, while bluebird bio priced its gene … WebSep 22, 2024 · Dive Brief: Bluebird bio, the Cambridge, Massachusetts-based drug developer, said Tuesday that its beti-cel gene therapy has been officially submitted for approval in the U.S., marking the latest step in what's become a protracted journey for the therapy. Beti-cel was tested in multiple early- and late-stage clinical trials as a one-time … truist bank pc app
UPDATE 1-Vertex/CRISPR
WebWith a dedicated focus on severe genetic diseases, bluebird has industry-leading programs for sickle cell disease, beta-thalassemia and cerebral … WebHbS causes RBCs to become fragile, rigid, and crescent—or sickle—shaped, which makes movement through blood vessels difficult, painful, and damaging to the body. This can result in severe anemia, blockage of blood vessels and progressive damage to the blood vessel walls (called vasculopathy). Webbluebird bio has the longest and most robust clinical program in transfusion-dependent beta‑thalassemia (TDT) in the field of gene therapy. The approval of ZYNTEGLO is … philip newton linkedin